Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as a triage in cervical screening: results of the sentinel sites study.

Legood R, Sadique Z, Patnick J, Kitchener H, Kelly R, Moss S.

Br J Cancer. 2012 Oct 23;107(9):1574-9. doi: 10.1038/bjc.2012.435. Epub 2012 Oct 4.

2.

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

Kim JJ, Wright TC, Goldie SJ.

J Natl Cancer Inst. 2005 Jun 15;97(12):888-95.

PMID:
15956650
3.
4.

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.

Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.

Gynecol Oncol. 2009 Feb;112(2):377-83. doi: 10.1016/j.ygyno.2008.08.030. Epub 2008 Dec 11.

PMID:
19081611
5.

Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.

Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P.

Can J Public Health. 2010 May-Jun;101(3):220-5.

PMID:
20737813
6.

Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden.

Ostensson E, Fröberg M, Hjerpe A, Zethraeus N, Andersson S.

Acta Obstet Gynecol Scand. 2010 Oct;89(10):1316-25. doi: 10.3109/00016349.2010.512066. Erratum in: Acta Obstet Gynecol Scand. 2010 Nov;89(11):1497.

PMID:
20846064
7.

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.

Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK.

Gynecol Oncol. 2010 Nov;119(2):237-42. doi: 10.1016/j.ygyno.2010.07.004. Epub 2010 Aug 14.

8.

[Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].

Magnani C, Gillio Tos A, De Marco L, Calvia M, Cipelletti A, Bestagini P, Pagano E, Segnan N, Ronco G.

Epidemiol Prev. 2012 Mar-Apr;36(2):88-94. Italian.

PMID:
22706358
9.

[Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].

Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33. Review. Italian.

10.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group.

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

PMID:
16418511
11.

Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.

van Rosmalen J, de Kok IM, van Ballegooijen M.

BJOG. 2012 May;119(6):699-709. doi: 10.1111/j.1471-0528.2011.03228.x. Epub 2012 Jan 18.

12.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

13.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
14.

HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study.

Kelly RS, Patnick J, Kitchener HC, Moss SM; NHSCSP HPV Special Interest Group.

Br J Cancer. 2011 Sep 27;105(7):983-8. doi: 10.1038/bjc.2011.326. Epub 2011 Sep 6.

15.

HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico.

Flores YN, Bishai DM, Lorincz A, Shah KV, Lazcano-Ponce E, Hernández M, Granados-García V, Pérez R, Salmerón J.

Cancer Causes Control. 2011 Feb;22(2):261-72. doi: 10.1007/s10552-010-9694-3. Epub 2010 Dec 18.

17.

Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis.

de Bekker-Grob EW, de Kok IM, Bulten J, van Rosmalen J, Vedder JE, Arbyn M, Klinkhamer PJ, Siebers AG, van Ballegooijen M.

Cancer Causes Control. 2012 Aug;23(8):1323-31. doi: 10.1007/s10552-012-0011-1. Epub 2012 Jun 17.

PMID:
22706692
18.

Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.

Del Mistro A, Frayle H, Ferro A, Callegaro S, Del Sole A, Stomeo A, Cirillo E, Fedato C, Pagni S, Barzon L, Zorzi M; Veneto HPV-screening Working Group.

J Med Screen. 2014 Mar;21(1):30-7. doi: 10.1177/0969141314522219. Epub 2014 Jan 31.

PMID:
24488593
19.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
20.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

Supplemental Content

Support Center